Deciphera Pharmaceuticals has been granted a patent for a method of treating tenosynovial giant cell tumors (TGCT) and diffuse-type tenosynovial giant cell tumors (DTGCT). The method involves administering a compound orally to the patient in a dosage range of 2 mg to 50 mg. GlobalData’s report on Deciphera Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Deciphera Pharmaceuticals, cancer treatment biomarkers was a key innovation area identified from patents. Deciphera Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treating tenosynovial giant cell tumor using a specific compound
A recently granted patent (Publication Number: US11679110B2) discloses a method for treating tenosynovial giant cell tumors and tumors expressing the receptor colony-stimulating factor 1 receptor (CSF1R) or its ligands. The method involves orally administering a compound represented by a specific formula to the patient.
The method described in the patent involves the oral administration of the compound to the patient. The dosage ranges from about 2 mg to about 50 mg, with specific dosages mentioned in some claims, such as about 5 mg to about 30 mg or about 20 mg. The compound is administered twice weekly for a specified duration, such as 6 months or 1 year.
The patent specifically mentions the treatment of tenosynovial giant cell tumors, particularly the diffuse-type, which is a type of benign tumor. The method can also be used to treat tumors known to express CSF1R, CSF1, or IL-34. The presence of these receptors or ligands can be determined by analyzing the patient's extracted tumor sample or extracellular fluid.
Overall, the granted patent provides a method for treating tenosynovial giant cell tumors and tumors expressing CSF1R, CSF1, or IL-34. The method involves the oral administration of a specific compound in varying dosages and frequencies. This patent may have implications for the development of new treatment options for these types of tumors.
To know more about GlobalData’s detailed insights on Deciphera Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
